BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou C, Zhang Y, Yu B, Phelps MA, Lee LJ, Lee RJ. Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes. Nanomedicine 2013;9:504-13. [PMID: 23117046 DOI: 10.1016/j.nano.2012.10.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Simonsson C, Bastiat G, Pitorre M, Klymchenko AS, Béjaud J, Mély Y, Benoit J. Inter-nanocarrier and nanocarrier-to-cell transfer assays demonstrate the risk of an immediate unloading of dye from labeled lipid nanocapsules. European Journal of Pharmaceutics and Biopharmaceutics 2016;98:47-56. [DOI: 10.1016/j.ejpb.2015.10.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
2 Alshehri A, Grabowska A, Stolnik S. Pathways of cellular internalisation of liposomes delivered siRNA and effects on siRNA engagement with target mRNA and silencing in cancer cells. Sci Rep 2018;8:3748. [PMID: 29491352 DOI: 10.1038/s41598-018-22166-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
3 Wen J, Moloney EB, Canning A, Donohoe E, Ritter T, Wang J, Xiang D, Wu J, Li Y. Synthesized nanoparticles, biomimetic nanoparticles and extracellular vesicles for treatment of autoimmune disease: Comparison and prospect. Pharmacol Res 2021;172:105833. [PMID: 34418563 DOI: 10.1016/j.phrs.2021.105833] [Reference Citation Analysis]
4 Paecharoenchai O, Teng L, Yung BC, Teng L, Opanasopit P, Lee RJ. Nonionic surfactant vesicles for delivery of RNAi therapeutics. Nanomedicine (Lond) 2013;8:1865-73. [PMID: 24156490 DOI: 10.2217/nnm.13.155] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
5 Sun M, Yang C, Zheng J, Wang M, Chen M, Le DQS, Kjems J, Bünger CE. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Acta Biomater 2015;28:171-82. [PMID: 26415776 DOI: 10.1016/j.actbio.2015.09.029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
6 Sun Y, Zhao Y, Zhao X, Lee RJ, Teng L, Zhou C. Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation. Molecules 2017;22:E1724. [PMID: 29027965 DOI: 10.3390/molecules22101724] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
7 Mihaila R, Ruhela D, Keough E, Cherkaev E, Chang S, Galinski B, Bartz R, Brown D, Howell B, Cunningham JJ. Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA. Molecular Therapy - Nucleic Acids 2017;7:246-55. [DOI: 10.1016/j.omtn.2017.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
8 Pengnam S, Plianwong S, Yingyongnarongkul BE, Patrojanasophon P, Opanasopit P. Delivery of small interfering RNAs by nanovesicles for cancer therapy. Drug Metab Pharmacokinet 2021;42:100425. [PMID: 34954489 DOI: 10.1016/j.dmpk.2021.100425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Jamili E, Dua V. Optimal model-based control of non-viral siRNA delivery. Biotechnol Bioeng 2018;115:1866-77. [DOI: 10.1002/bit.26596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Paecharoenchai O, Niyomtham N, Leksantikul L, Ngawhirunpat T, Rojanarata T, Yingyongnarongkul BE, Opanasopit P. Nonionic surfactant vesicles composed of novel spermine-derivative cationic lipids as an effective gene carrier in vitro. AAPS PharmSciTech 2014;15:722-30. [PMID: 24623349 DOI: 10.1208/s12249-014-0095-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
11 Obeid MA, Elburi A, Young LC, Mullen AB, Tate RJ, Ferro VA. Formulation of Nonionic Surfactant Vesicles (NISV) Prepared by Microfluidics for Therapeutic Delivery of siRNA into Cancer Cells. Mol Pharmaceutics 2017;14:2450-8. [DOI: 10.1021/acs.molpharmaceut.7b00352] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
12 Yung BC, Li J, Zhang M, Cheng X, Li H, Yung EM, Kang C, Cosby LE, Liu Y, Teng L, Lee RJ. Lipid Nanoparticles Composed of Quaternary Amine–Tertiary Amine Cationic Lipid Combination (QTsome) for Therapeutic Delivery of AntimiR-21 for Lung Cancer. Mol Pharmaceutics 2016;13:653-62. [DOI: 10.1021/acs.molpharmaceut.5b00878] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
13 Zhang J, Liu J, Zhao Y, Wang G, Zhou F. Plasma and cellular pharmacokinetic considerations for the development and optimization of antitumor block copolymer micelles. Expert Opin Drug Deliv 2015;12:263-81. [PMID: 25217414 DOI: 10.1517/17425247.2014.945417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
14 Yang C, Gao S, Song P, Dagnæs-hansen F, Jakobsen M, Kjems J. Theranostic Niosomes for Efficient siRNA/MicroRNA Delivery and Activatable Near-Infrared Fluorescent Tracking of Stem Cells. ACS Appl Mater Interfaces 2018;10:19494-503. [DOI: 10.1021/acsami.8b05513] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
15 Yu B, Wang X, Zhou C, Teng L, Ren W, Yang Z, Shih CH, Wang T, Lee RJ, Tang S, Lee LJ. Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs. Pharm Res 2014;31:2685-95. [PMID: 24740244 DOI: 10.1007/s11095-014-1366-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
16 Yu H, Teng L, Meng Q, Li Y, Sun X, Lu J, J Lee R, Teng L. Development of liposomal Ginsenoside Rg3: formulation optimization and evaluation of its anticancer effects. Int J Pharm 2013;450:250-8. [PMID: 23628402 DOI: 10.1016/j.ijpharm.2013.04.065] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
17 Duechler M. Vehicles for Small Interfering RNA transfection: Exosomes versus Synthetic Nanocarriers. DNA and RNA Nanotechnology 2013;1. [DOI: 10.2478/rnan-2013-0002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
18 Grijalvo S, Puras G, Zárate J, Sainz-Ramos M, Qtaish NAL, López T, Mashal M, Attia N, Díaz D, Pons R, Fernández E, Pedraz JL, Eritja R. Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery. Pharmaceutics 2019;11:E50. [PMID: 30678296 DOI: 10.3390/pharmaceutics11020050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
19 Tushir-Singh J. Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. Expert Opin Biol Ther 2017;17:325-38. [PMID: 27977315 DOI: 10.1080/14712598.2017.1273344] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]